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Environmental pollutants and industrial
chemicals disrupt—and have the potential to
alter—the action of gonadal steroid hormones
by virtue of their antiandrogenic or estrogenic
properties and, in so doing, effect hormonal
balance (Foster 2006; Foster and McIntyre
2002; Kelce and Wilson 1997). During fetal
and neonatal life, reproductive tract develop-
ment is hormonally regulated, and the repro-
ductive tract is in an undifferentiated state,
lacking compensatory homeostatic mecha-
nisms to prevent adverse effects of endocrine-
disrupting chemicals (EDCs) (Cunha et al.
1992; Prins 1997). Thus, the organizational
effects of EDCs on the developing reproduc-
tive tract can be permanent and irreversible.
Dissimilar to prostate cancer (PCa) and
benign prostate hyperplasia (BPH), which
predominantly affect aging men, prostate
inﬂammation (prostatitis) affects 9% of men
of all ages (McNaughton-Collins et al. 2007).
Most (> 90%) prostatitis cases are ascribed to
unknown (nonbacterial) origins, and the
symptoms, both acute and chronic, are com-
mon, bothersome, and burdensome in terms
of health-related quality of life (McNaughton
Collins et al. 2001; Turner et al. 2005). The
economic impact of prostatitis includes an
estimated annual expenditure in the United
States of > $84 million for diagnosis and
management, excluding subsequent pharma-
ceutical costs (Calhoun et al. 2004; Litwin
and Saigal 2007; McNaughton-Collins et al.
2007). Because there are extensive gaps in our
understanding of prostatitis etiology, many of
these current expenditures may be ineffective
and a waste of resources. Thus, it is impera-
tive that we better understand this disease,
one that has received relatively little attention
compared with BPH and PCa.
Although increased levels of develop-
mental or environmental estrogens have been
linked to the increased incidence of prostate
disease (Coffey 2001; Harkonen and Makela
2004), chemicals with antiandrogenic activity
are potentially of greater importance because
androgens are critical to establishing the male
phenotype. Vinclozolin [3-(3,5-dichloro-
phenyl)-5-methyl-oxazolidine-2,4-dione] is an
antiandrogenic systemic dicarboximide fungi-
cide used widely throughout Europe and the
United States to control diseases caused by
Botrytis cinerea, Sclerotinia sclerotiorum, and
Moniliniam spp. Vinclozolin is degraded to
the metabolites 2-[(3,5-dichlorophenyl)-
carbamoyl]oxy-2-methyl-3-butenoic acid
(M1) and 3´,5´-dichloro-2-hydroxy-2-methyl-
but-3-enanilide (M2), which are competitive
antagonists of androgen receptor (AR) ligand
binding, rather than 5α-reductase enzyme
inhibitors (Kelce et al. 1994; Wong et al.
1995). When sprayed as Ronilan (a 50% mix-
ture of vinclozolin; BASF AG, Research
Triangle Park, NC, USA) on soil, vinclozolin
has a half-life of 23 days (Szeto et al. 1989).
Previous reports show that vinclozolin expo-
sure in rodents during reproductive tract
development induces malformations such as
cryptorchidism, hypospadias, and Leydig cell
hyperplasia, and permanent changes in sexu-
ally dimorphic structures, such as anogenital
distance (AGD) and areola/nipple retention
(Gray et al. 1994). These effects occur before
formation of the hypothalamic–pituitary–
gonadal axis and long after vinclozolin has
been cleared from the pup; thus, these effects
are organizational rather than due to interrup-
tion of a feedback loop via the pituitary.
Recent interest in vinclozolin arose from a
report that transient embryonic exposure in
the rat during embryonic gonadal sex determi-
nation [gestation days (GD) 8–14] appears to
alter the male germline epigenome and subse-
quently promotes transgenerational adult-
onset disease, including testis and immune
abnormalities, prostate and kidney disease, and
tumor development (Anway et al. 2005). In a
preliminary report, Anway et al. (2006) stated
that prostate disease, including inﬂammation
and epithelial atrophy, occurred in aged rats
(12–14 months of age) prenatally exposed to
vinclozolin, although the incidence of prostatic
lesions across four generations of male rats was
only 10%. Although the low incidence of pro-
static lesions is not compelling, at the same
time these ﬁndings were controversial because
of the vinclozolin purity and the timing and
route of its administration in utero. 
The purity of vinclozolin was not demon-
strated by Anway et al. (2006), and vinclo-
zolin, when purchased commercially, requires
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BACKGROUND: Androgens are critical for specifying prostate development, with the fetal prostate
sensitive to altered hormone levels and endocrine-disrupting chemicals (EDCs) that exhibit estro-
genic or antiandrogenic properties. Prostatic inflammation (prostatitis) affects 9% of men of all
ages, and > 90% of cases are of unknown etiology. 
OBJECTIVES: In this study we aimed to evaluate effects of in utero exposure to the antiandrogenic
EDC vinclozolin, during the period of male reproductive tract development, on neonatal, pre-
pubertal, and postpubertal prostate gland function of male offspring. 
METHODS: Fetal rats were exposed to vinclozolin (100 mg/kg body weight) or vehicle control
(2.5 mL/kg body weight) in utero from gestational day 14 (GD14) to GD19 via oral administration
to pregnant dams. Tissue analysis was carried out when male offspring were 0, 4, or 8 weeks of age.
RESULTS: In utero exposure to vinclozolin was insufﬁcient to perturb prostatic development and
branching, although expression of androgen receptor and mesenchymal ﬁbroblast growth factor-10
was down-regulated. Prostate histology remained normal until puberty, but 100% of animals dis-
played prostatitis postpubertally (56 days of age). Prostatic inﬂammation was associated with phos-
phorylation and nuclear translocation of nuclear factor-kappa B (NFκB) and postpubertal
activation of proinﬂammatory NFκB-dependent genes, including the chemokine interleukin-8 and
the cytokine transforming growth factor-β1. Signiﬁcantly, inﬂammation arising from vinclozolin
exposure was not associated with the emergence of premalignant lesions, such as prostatic intra-
epithelial neoplasia or proliferative inﬂammatory atrophy, and hence mimics nonbacterial early-
onset prostatitis that commonly occurs in young men. 
CONCLUSIONS: These data are the ﬁrst to unequivocally implicate EDCs as a causative factor and
ﬁll an important knowledge gap on the etiology of prostatitis.
KEY WORDS: antiandrogen, endocrine disruptors, inﬂammation, prostate, prostatitis, vinclozolin.
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http://dx.doi.org/ [Online 26 March 2008]purification and recrystallization to obtain
> 99% purity to ensure that effects are not
caused by contaminants. Human exposure to
vinclozolin occurs by oral ingestion, enabling
metabolism to the more potent AR antagonists
(M1 and M2). Direct intraperitoneal adminis-
tration runs the risk of producing effects not
observed by the conventional oral route, such
as uterine irritation and changes in uterine
blood ﬂow. The timing of vinclozolin exposure
also varies the effect on male reproductive tract
development in rodents. A window of sensitiv-
ity for prostate development occurs when ARs
are activated between GD14 and GD19,
rather than during embryonic gonadal sex
determination around GD8–GD14 (Wolf
et al. 2000). Commonly, the outcomes of any
transient in utero treatments are examined in
aging animals. However, antiandrogenic
effects also manifest at other times, including
pre- and postpuberty, when hormone action is
critical for normal prostate maturation and
function. Altogether, these variations in treat-
ment protocol may account for the low inci-
dence of prostatic lesions reported by Anway
et al. (2005), who used intraperitoneally
administered unpurified vinclozolin during
GD8–GD14 and did not study outcomes
until 12–14 months of age.
Therefore, the aim of this study was to
evaluate effects of fetal exposure to purified
vinclozolin, administered orally to pregnant
rats during the period of male reproductive
tract development (GD14–GD19), on pre-
and postpubertal prostate gland function in
male offspring.
Material and Methods
Animals. We conducted all animal procedures
according to National Health and Medical
Research Council guidelines and the animal
experimentation ethics committee at Monash
Medical Centre (MMCA/2006/22). Animals
were treated humanely and with regard for
alleviation of suffering. Time-mated female
outbred Sprague-Dawley rats were obtained
from Monash University Central Animal
Services on GD8 and housed at Monash
Medical Centre Animal House under con-
trolled 12-hr light/dark cycle and temperature
conditions. Animals were fed ad libitum.
GD0 was the day vaginal plugs were observed
in mated females. Dams and offspring were
housed together until weaning [postnatal day
(PND) 21], when male litter mates were
group-housed, no more than four per cage.
Dams and female offspring were euthanized
humanely by CO2 asphyxiation and were not
subjected to postmortem examination.
Vinclozolin. We obtained vinclozolin
from BASF AG (Research Triangle Park,
NC, USA) as Ronilan EG (a 50% vinclozolin
mixture). We purified and recrystallized the
compound. Catalogued as lot no. 357-141A,
it was certified as being of > 99% purity by
ChemService Inc. (West Chester, PA, USA).
Treatment. We performed the treatment
regime as previously described (Wolf et al.
2000). On GD14, dams were weighed and
allocated to treatment groups by body weight
(bw) randomization to ensure unbiased
weight distribution among groups. Dams
were assigned to one of two treatment groups
(0 and 100 mg vinclozolin per kilogram bw;
n = 16 dams per group) and one of three
time points of collection [PND0 (n = 8),
PND28 (n = 4), and PND56 (n = 4). Dams
were orally dosed daily at 1000 hours on
GD14–GD19 with 100 mg/kg/bw vinclo-
zolin or corn oil vehicle (2.5 mL/kg/bw;
Sigma Chemical Co., St. Louis, MO, USA)
and examined for clinical signs of toxicity.
The dose chosen corresponds to a level com-
monly used to investigate vinclozolin effects
on male reproductive tract formation, induc-
ing an array of male reproductive tract mal-
formations at high incidence without
maternal toxicity. Because the pubertal
period in the rodent is controversial, puberty
has been defined in relation to functional
puberty or the time at which sperm appear
and serum testosterone rises. This occurs
around PND43 in rats (Korenbrot et al.
1977; Stoker et al. 2000).
Necropsy of male littermates. Male off-
spring were collected at PND0, PND28, or
PND56; each animal was weighed and eutha-
nized by decapitation (PND0) or CO2
asphyxiation (PND28 and PND56), and
blood was collected by cardiac puncture for
hormonal analysis. External genitalia, includ-
ing scrotum, prepuce, and penis, were visually
examined, and AGD was measured with a
caliper.
Hormone analysis. Serum testosterone
levels were measured by ANZAC Research
Institute (Sydney, Australia) as previously
described (Ly et al. 2001).
Tissue collection. Using a dissecting micro-
scope (SZX12, Olympus Corp., Tokyo, Japan)
and dissecting tools, testes, seminal vesicles
(SV), and ventral (VP), dorsal (DP), lateral
(LP), and anterior (AP) prostate lobes were
dissected from PND28 and PND56 animals
and wet weights were recorded. For isolation
of PND0 prostates, urogenital tracts were
removed and VPs microdissected in a modiﬁed
watch glass (Maximov depression slide; Fisher,
Pittsburgh, PA, USA) in the presence of dis-
secting media [basal medium of Dulbecco’s
modiﬁed Eagle’s medium and Hams F-12 (1:1
vol/vol) supplemented with penicillin and
streptomycin (5 mL/L) and fungizome
(20 µg/mL) at pH 7.3]. Pair-matched organs
were ﬁxed in Bouin’s ﬁxative or immediately
frozen in liquid nitrogen and stored at –80°C.
Tissue separation. PND0 VPs for epithe-
lial and mesenchymal RNA analysis were
digested in 1% trypsin (Difco, Detroit, MI,
USA) in Hank’s calcium- and magnesium-
free balanced salt solution (Gibco, Invitrogen,
Mount Waverley, Victoria, Australia) for
60 min. Mesenchyme and epithelia were
mechanically separated, immediately frozen in
liquid nitrogen, and stored at –80°C.
Histology. Fixed tissues were dehydrated,
processed, and embedded in paraffin. Serial
5-µm sections were cut and mounted onto
Superfrost Plus+ coated slides (Menzel-Glaser,
Braunschweig, Germany). Tissue sections were
stained with Harris’s hematoxylin and eosin
(H&E) or used for immunohistochemisty.
Immunohistochemistry was performed using
the DAKO Autostainer Universal Staining
System (DAKO A/S, Glostrup, Denmark)
(Balanathan et al. 2004). We purchased the
following antibodies from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA):
AR (N-20), transforming growth factor-β1
(TGF-β1; SC-146), toll-like receptor-4
(TLR4), and fibroblast growth factor 10
(Fgf10; H-121:SC_7917). We obtained prolif-
erating cell nuclear antigen (PCNA; clone
PC10) from DAKO; CD68 (ED1) from
Sapphire Bioscience Pty Ltd. (Redfern, New
South Wales, Australia); and phospho-NFκB
p65 (Ser536) from Cell Signaling Technology
Inc. (Danvers, MA, USA). Antibodies were
used as previously described (Bianco et al.
2002; Laczkó et al. 2004; Wang et al. 2001) or
according to manufacturer speciﬁcations.
mRNA extraction. Total RNA was
extracted from prostate tissues using TRIzol
reagent (Invitrogen Life Technologies,
Rockville, MD, USA) according to manufac-
turer specifications and as previously
described (Balanathan et al. 2004).
Oligo gene expression analysis. We con-
ducted gene expression analysis using
GEArray DNA microarray (for PND56, array
ERN-011.2; for PND0, array EMM-014;
SuperArray Bioscience Corp., Frederick, MD,
USA) according to manufacturer’s directions.
Analysis was conducted on a minimum of
four samples per group in duplicate. Briefly,
cDNA was synthesized from pure RNA using
the TrueLabelling-AMP 2.0 kit (SuperArray
Bioscience). cDNA was ampliﬁed followed by
a 24-hr cRNA synthesis reaction. cRNA con-
centration and purity were determined by
ultraviolet spectrophotometry. After genera-
tion and puriﬁcation of cRNA, we performed
array hybridization using the Oligo GEArray
HybPlate Basic Protocol (SuperArray
Bioscience) according to the manufacturer’s
directions. Briefly, arrays were subjected to
prehybridization before hybridization with the
labeled target cRNA, incubated for 24 hr at
60°C, and then subject to repeated stringency
washes. Chemiluminescence was detected
using the Chemiluminescent Detection Kit
(SuperArray Bioscience). Briefly, arrays were
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line phosphatase–streptavidin for 10 min,
rinsed in buffer, and incubated with CDP-Star
chemiluminescent detection reagent. Images
were acquired immediately using X-ray expo-
sure. X-ray images were captured using a scan-
ner and saved as 16-bit TIFF images. We
completed data analysis using GEArray
Expression Analysis Suite (SuperArray
Bioscience), with expression normalized to a
speciﬁc set of housekeeping genes [ribosomal
protein L32 (Rpl32), lactate dehydrogenase A
(Ldha), glyceraldehyde 3-phosphate dehydro-
genase (Gadph), peptidylprolyl isomerase A
(Ppia)].
Stereology. We obtained an unbiased esti-
mate of the terminally differentiated secretory
epithelial cell population and incidence of
inflammation using stereological techniques,
based on the Cavalieri principle (Bertram
1995) and as previously described in the testes
and prostate (McPherson et al. 2001;
Meachem et al. 1996; Singh et al. 1999).
Stereological analysis was performed using a
BX-51 microscope (Olympus) and a JVC
TK-C1380 video camera (Victor Company of
Japan Ltd., Yokohama, Japan) coupled to a
computer. Images were projected directly onto
a video screen; using CAST version 1.10 soft-
ware (Computer Assisted Stereological
Toolbox; Olympus Danmark A/S, Ballerup,
Denmark), tissue sections were mapped at 40×
magnification to define tissue boundaries.
Beginning from a random point, sampling was
conducted at predetermined intervals along x-
and y-axes using a 3 × 3-point grid counting
frame. We used a minimum of 10 sections per
animal, uniformly spaced throughout explants,
and ﬁve animals per group. To accurately dif-
ferentiate terminally differentiated secretory
epithelial cells, we used tissue sections stained
for high-molecular-weight cytokeratin
(CKHMW); positively and negatively stained
CKHMW cells were identified and percent-
ages of positive and negative cells determined.
To determine the incidence of inﬂammatory
lesions, random ﬁelds were designated as posi-
tive or negative for inﬂammation. Abnormal
inflammatory regions were classified as areas
that displayed chronic inﬂammation.
Wholemount immunolabeling. We con-
ducted branching morphogenesis analysis on
PND0 VPs. Individual VPs were placed in
methanol and stored at –20°C. Immuno-
labeling was performed as previously described
by Almahbobi and Hall (1993). Brieﬂy, tissues
were permeabilized in 0.2% (vol/vol) Triton
X-100 (Sigma) and 5 µg/mL sodium borohy-
dride in phosphate-buffered saline (pH 8.0)
for 15 min. Nonspeciﬁc binding was blocked
with Superblock blocking buffer (Pierce,
Rockford, IL, USA) for 1 hr at room tempera-
ture, before overnight incubation at 4°C with
a monoclonal mouse anti-human CKHMW
(5 µg/mL IgG; Dako Corp., Carpinteria, CA,
USA). Tissues were incubated with 5 µg/mL
goat anti-mouse IgG secondary antibody
(F[ab]2 fragments) conjugated with ﬂuorescein
isothiocyanate (Dako Corp.) for 90 min at
room temperature. VPs were mounted on
slides using Vectorshield ﬂuorescent mounting
medium (Vector Labs, Burlingame, CA, USA)
with coverslips mounted on nail polish plat-
forms, to maintain three-dimensional patterns.
Analysis of branching morphogenesis.
We generated serial optical images of
CKHMW-stained whole-mount tissues at
2 µm interframe steps using an Olympus con-
focal microscope, and captured and stored
them in 8-bit BMP format using Fluroview
software (Olympus) as previously described
(Almahbobi et al. 2005). Confocal images
were subsequently used to construct a three-
dimensional skeleton representing the original
ductal pattern of the gland, using lines run-
ning through the center of each ductal/epithe-
lial branch. A full description of this process
was previously reported for the study of
branching morphogenesis in kidney (Cullen-
McEwen et al. 2002; Fricout et al. 2001) and
prostate (Almahbobi et al. 2005). The resul-
tant algorithm provides fully automated meas-
urements of the branch length (in pixels and
micrometers) and cumulative surface areas (in
square pixels) of the individual ducts as they
appear in all the frames. Total ductal length
was calculated by adding together individual
branch lengths from multiple ducts within a
lobe. The value of the surface areas was multi-
plied by 1.5522 (pixel area) to convert it into
micrometers, and then by 2 (for 2-µm inter-
frame steps) to obtain total volume (in cubic
micrometers) of individual ducts. Numbers of
branch points, branches, and terminal tips
were automatically generated by the software.
Statistical analysis. All pup data was ana-
lyzed individually and nested by dam to yield
litter means. To test for signiﬁcance of treat-
ment effects, we corrected for litter as a main
effect variable using one-way analysis of
covariance on SPSS, version 16 (SPSS Inc.,
Chicago, IL, USA); data are expressed as litter
mean ± SE. AGD and organ weights were
analyzed with body weight as a covariate.
Control and vinclozolin were compared using
an F-test, with the significance threshold at
5% (p < 0.05). Analysis of control and vinclo-
zolin stereological data was performed using a
two-tailed paired t-test using Prism 4.0 soft-
ware (GraphPad Software, Inc., San Diego,
CA, USA).
Results
PND0 litter data. We compared pregnant
Sprague-Dawley rats transiently exposed to
vinclozolin (100 mg/kg/day) on GD14–
GD19 with corn oil–treated controls
(2.5 mL/kg/day). Vinclozolin did not induce
maternal toxicity or affect normal pregnancy:
no dams presented dystocia or delivered late.
Dam weight gain through the dosing period
was not signiﬁcantly different between groups
(Table 1). Vinclozolin treatment did not
affect live litter size or sex ratio, with sex con-
ﬁrmed in offspring at puberty (Table 1).
Gross analysis of male offspring after
in utero treatment. We analyzed male offspring
exposed in utero on PND0 (day of birth),
PND28 (prepubertal), and PND56 (post-
pubertal) for any weight differences or gross
morphologic abnormalities. Pup weights
on PND0 were significantly lower in the
vinclozolin-treated group compared with the
control group (p < 0.05) (Table 1), but no sig-
niﬁcant changes in body weight were observed
on PND28 or PND56 (p < 0.05; Table 2).
AGD, a sensitive indicator of antiandrogenicity,
was signiﬁcantly reduced at all ages in the vin-
clozolin group compared with controls
(Tables 1 and 2). Covariate analysis demon-
strated that the PND0 AGD reductions were
not due to pup weight reductions. 
On PND28, compared with controls,
vinclozolin treatment did not significantly
reduce testis, SV, VP, AP, DP, or LP weights
(p < 0.05) (Table 2). Analysis of external geni-
talia revealed undescended testes in 35.93 ±
4.37% of prepubertal animals exposed to vin-
clozolin, compared with none in the control
group. At PND56, vinclozolin treatment sig-
nificantly reduced SV and VP weights and
significantly increased AP weight (p < 0.05)
(Table 2). We observed no signiﬁcant differ-
ences in LP, DP, and testis weights (Table 2).
Malformations of external genitalia included
cleft prepuce, incomplete preputial separation,
Endocrine disruptor–induced prostatitis
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Table 1. Effects of 6-day exposure to corn oil (control) or vinclozolin on PND0 in dams and pups.
End point Control Vinclozolin
Dams assigned 16 16
Dams pregnant 12 13
Dams delivered late 0 0
Dam weight gain through dosing period (g) 49.29 ± 10.38 53.33 ± 11.81
Live litter size 12.18 ± 2.26 12.83 ± 2.33
Male:female ratio at birth 1.10 ± 0.67 1.61 ± 1.80
Pup weight at birth (g) 6.44 ± 0.07 6.16 ± 0.09*
AGD in male offspring at birth 4.36 ± 0.08 3.75 ± 0.10*
Values shown are number or mean ± SE.
*p < 0.05.cleft phallus, and hypospadias, observed in
47.02 ± 7.92% of postpubertal animals
exposed to vinclozolin compared with none
in controls. Analysis of serum testosterone
levels revealed no significant differences
between control and vinclozolin groups at any
postnatal age (Figure 1).
Although we collected and analyzed all
prostate lobes, we report here only data for
the VP because, in addition to being the most
commonly reported lobe with respect to EDC
exposures, it is the most androgen-sensitive
lobe (Prins and Birch 1995; Risbridger et al.
2001); therefore, the actions of an anti-
androgenic chemical are more likely to induce
effects in this lobe.
Absence of perturbations in branching
morphogenesis in neonatal offspring. The
inductive and instructive potential of the
mesenchyme and importance of mesenchymal
androgen signaling in normal prostate
branching and development have been well
established. To examine whether in utero
vinclozolin exposure perturbed normal
mesenchymal signaling in offspring, we per-
formed gene array analysis of 113 common
growth factors on neonatal mesenchyme.
Significant (> 1.5-fold) down-regulation
occurred for several mesenchymal genes,
including Fgf10, in prostates from animals
exposed in utero to vinclozolin compared with
controls; this was confirmed by immuno-
protein localization (data not shown). Because
estrogen exposure down-regulates Fgf10 and
perturbs normal prostate ductal branching
(Huang et al. 2005), we investigated whether
the antiandrogen-induced reduction in mes-
enchymal Fgf10 was associated with develop-
mental abnormalities. 
We analyzed branching morphogenesis in
neonatal tissues using a computer-based
method that allows examination of temporal
and spatial alterations in branching morpho-
genesis as a result of experimental manipula-
tions. Despite mesenchymal Fgf10 reductions,
prostate size was normal, with no signiﬁcant
differences present in ductal number, length,
volume, or branch points in neonatal speci-
mens between prostates from animals in the
vinclozolin group compared with controls
(Figure 2).
Normal prostate development until
puberty with early onset of prostate inflam-
mation in postpubertal offspring. We
observed no gross morphologic differences
between in utero vinclozolin and control
treatment in PND28 (prepubertal) prostates
(Figure 3A,B). However, analysis of prostate
specimens at PND56 (postpubertal) revealed
the onset of prostate inﬂammation in in utero
vinclozolin-exposed males (Figure 3C,D). We
observed prominent, but focal, regions of
inflammation in 100% of animals, with an
increase in the proportion of inflammatory
cells, particularly leukocytes and macro-
phages, surrounding the ducts and inﬁltrating
the vessels (Figure 3D). Increased macro-
phage infiltration was evident in prostates
from animals exposed to vinclozolin, as
demonstrated by immunolocalization of ED1
(Figure 3E,F), but was absent in control
animals. In utero vinclozolin treatment
resulted in a signiﬁcant increase (p < 0.05) in
the percentage of prostatic inflammatory
lesions, identiﬁed by stereological analysis, from
1.4 ± 0.80% to 16.8 ± 3.72% (Figure 3G).
Proinflammatory stimuli and immune
responses are commonly controlled by the
nuclear factor-kappa B (NFκB) family of
transcription factors. In unstimulated cells,
NFκB is sequestered in the cytoplasm of cells
and activated when it is phosphorylated and
translocated to the nucleus. We confirmed
activation of NFκB in prostates exposed
in utero to vinclozolin by nuclear immuno-
protein localization of phospho-NFκB p65
(Ser536) antibody, which detects NFκB p65
only when phosphorylated at serine 536. In
control prostates, we identiﬁed few immuno-
positive cells (Figure 3H,I).
Activation of NFκB subsequently induces
transcription of many NFκB-dependent genes,
including those encoding inflammatory
cytokines and chemokines. To determine the
distinct pattern of gene expression after activa-
tion of NFκB signaling by vinclozolin treat-
ment, we performed pathway-specific gene
array analysis of 113 key genes involved in the
inflammatory response. We observed signifi-
cant (> 1.5-fold) up- and down-regulation of
69 and 34 genes, respectively, in prostate tissues
of vinclozolin-exposed PND56 animals com-
pared with controls (Table 3). These data show
increased activation of classic proinﬂammatory
NFκB-dependent genes, including chemokines
such as interleukin-1α (IL-1α), IL-6, and IL-8
and cytokines such as TGF-β and tumor necro-
sis factor-α (TNF-α), as well as other ligands
and receptors, including TLR1–TLR6, TLR9,
and TNF receptors.
We selected several key NFκB-dependent
genes to examine transcriptional activity by
immunoprotein localization, including TLR4
and TGF-β1. We conﬁrmed heightened expres-
sion of TLR4, an important innate immune
receptor, by increased immunoprotein localiza-
tion, particularly in the stromal and periductal
compartments of tissues from vinclozolin-
exposed animals (Figure 3J,K). We observed a
significant up-regulation of TGF-β1 expres-
sion in tissues from the vinclozolin group
Cowin et al.
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Figure 1. Effects of 6-day exposure to vinclozolin or
corn oil (control) on serum testosterone (mean ±
SE) on PND0, PND28, or PND56.
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Figure 2. Effects of in utero exposure to corn oil (control) or vinclozolin on branching morphogenesis in the
prostate of PND0 males. Neither ductal number, length, and volume (A) nor number of branches, points,
and tips (B) revealed signiﬁcant differences between treatment groups. Values shown are mean ± SE.
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Table 2. Effects of 6-day exposure to corn oil (control) or vinclozolin on reproductive organ weights (litter
mean ± SE) in male offspring on PND28 and PND56.
Control Vinclozolin
End point PND28 PND56 PND28 PND56
Body weight (g) 70.97 ± 0.61 259.09 ± 7.21 73.6 ± 1.25 275.29 ± 5.02
AGD (mm) 25.55 ± 0.54 40.51 ± 0.91 24.20 ± 0.33* 30.82 ± 1.31*
VP weight (mg) 37.67 ± 1.45 223.74 ± 6.81 35.38 ± 1.25 199.16 ± 6.09*
AP weight (mg) 4.56 ± 0.55 69.32 ± 3.67 4.27 ± 0.32 82.23 ± 3.23*
LP weight (mg) 7.3 ± 0.49 45.68 ± 4.04 5.73 ± 0.61 56.69 ± 3.63
DP weight (mg) 9.1 ± 1.23 61.26 ± 4.42 9.15 ± 0.71 73.25 ± 3.98
SV weight (mg) 11.61 ± 0.96 507.94 ± 15.14 12.96 ± 0.58 373.15 ± 13.56*
Testis weight (g) 0.525 ± 0.02 2.41 ± 0.06 0.484 ± 0.01 2.58 ± 0.05
*p < 0.05.(Figure 3L,M), correlating with a significant
down-regulation of the immunosuppressive
cytokine and TGF-β1–negative regulator
IL-10 (Table 3).
Epithelial aberrations in postpubertal off-
spring without evidence of premalignancy. In
addition to the 100% penetrance of prostatic
inflammation observed in PND56 prostate
specimens, in utero exposure to vinclozolin
also induced focal epithelial attenuation
(reduction in epithelial cell height and thin-
ning of ductal structure) in all animals. We
Endocrine disruptor–induced prostatitis
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Figure 3. Effect of in utero exposure to vinclozolin on early-onset postpubertal prostatitis. (A–F) Photomicrographs showing morphology of prostates from control
(A,C,E) and vinclozin-exposed (B,D,F) rats. Prepubertally, no morphologic differences were identiﬁed between prostates in the two groups (A,B). Prostates from
controls (C) showed extensive ductal branching and canalization, with pseudostratiﬁed columnar epithelial cells lining the ducts and continuous stromal sheaths
surrounding the ducts; however, in prostates from vinclozolin-exposed rats (D), prominent but focal regions of inﬂammation are evident. Compared with controls (E),
an increase in the proportion of macrophages surrounding the ducts and inﬁltrating into vessels is evident after vinclozolin treatment (F). (G) Percentage of inﬂam-
mation (mean ± SE) in prostates of control and vinclozolin-exposed rats. (H–M) Photomicrographs of prostates from control (H,J,L) and vinclozin-exposed (I,K,M)
rats immunostained for phospho-NFκB p65 (Ser536) (H,I), TLR-4 (J,K), and TGF-β1( L,M). Compared with control tissues (H), activation of the inﬂammatory NFκB
pathway was evident in prostates from vinclozolin-treated animals, with increased nuclear immunoprotein localization of phospho-NFκB p65 (Ser536) (I and inset).
(J–M) Compared with control prostates (J), vinclozolin-exposed prostates showed NFκB-dependent up-regulated expression of the Tlr4 gene (K) and an increase in
TGF-β1 expression (L, M). The inset in L is an IgG-matched negative control. Bars = 50 µm in A–D, H, I, L, and M; 20 µm in E and F; and 100 µm in J, and K.
*p < 0.05.
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Table 3. Effects of 6 day in utero exposure to vinclozolin on key NFκB-dependent inﬂammatory genes on PND56 compared with corn oil (control) treatment.
UniGenea Symbol Description Fold difference
Rn.12300 Il1a Interleukin 1 alpha 5.05
Rn.9869 Il1b Interleukin 1 beta 2.02
Rn.1716 Il6ra Interleukin 6 receptor, alpha 5.16
Rn.12138 Il6st Interleukin 6 signal transducer 11.13
Rn.138115 Il8ra Interleukin 8 receptor, alpha 7.80
Rn.90347 Il8rb Interleukin 8 receptor, beta 4.29
Rn.92374 Il9 Interleukin 9 3.52
Rn.10045 Il9r Interleukin 9 receptor 1.96
Rn.54465 Itgam Integrin alpha M 3.34
N/A LOC301289 Similar to interleukin-17 precursor (IL-17) (cytotoxic T lymphocyte-associated antigen 8) (CTLA-8) 13.43
Rn.2661 Mif Macrophage migration inhibitory factor 9.19
Rn.10400 Nos2 Nitric oxide synthase 2, inducible 19.35
Rn.29157 Rac1 Ras-related C3 botulinum toxin substrate 1 9.89
Rn.40136 Tgfb1 Transforming growth factor, beta 1 27.30
Rn.107212 Tlr1 Similar to toll-like receptor 1 (LOC305354), mRNA 18.47
Rn.46387 Tlr2 Toll-like receptor 2 27.23
Rn.15273 Tlr3 Toll-like receptor 3 31.22
Rn.14534 Tlr4 Toll-like receptor 4 14.04
Rn.198962 Tlr5 Toll-like receptor 5 14.86
Rn.163249 Tlr6 Toll-like receptor 6 14.42
Rn.92495 Tlr9 Toll-like receptor 9 22.90
Rn.2275 Tnf Tumor necrosis factor (TNF superfamily, member 2) 27.49
Rn.11119 Tnfrsf1a Tumor necrosis factor receptor superfamily, member 1a 23.49
Rn.83633 Tnfrsf1b Tumor necrosis factor receptor superfamily, member 1b 29.62
Rn.30043 Tnfsf4 Tumor necrosis factor (ligand) superfamily, member 4 16.82
Rn.44218 Cd40lg CD40 ligand 9.51
Rn.9868 Il10 Interleukin 10 0.44
Rn.50003 Il17b Interleukin 17B 0.79
Rn.11118 Il18 Interleukin 18 0.92
aData from National Center for Biotechnology Information (2008).observed a reduction in epithelial AR concur-
rently with a reduction in terminally differen-
tiated secretory epithelia (Figure 4A,B).
Immunolocalization of the basal cell marker
CKHMW (Figure 4C,D) showed loss of ter-
minally differentiated secretory epithelia and
epithelial attenuation, evidenced by a contin-
uous layer of basal cells compared with a dis-
continuous layer observed in control,
conﬁrmed by stereologic analysis (Figure 4E).
Prostatic inflammation associated with
atrophy and proliferation [known as prolifera-
tive inflammatory atrophy (PIA)] has been
reported as a premalignant lesion in men.
Although PIA has not been confirmed in
rodents, we examined proliferative activity by
immunolocalization of PCNA (Figure 4F,G).
Epithelial attenuated glands of tissues exposed
in utero to vinclozolin showed an apparent loss
of proliferative activity with a reduction in
immunopositive epithelial cells, demonstrating
the absence of pathology comparable with PIA
in these tissues. There was no evidence of
other prostatic lesions, such as premalignant
prostatic intraepithelial neoplastic lesions.
Discussion
The role of EDCs in the early origins of adult
prostate disease is of concern and controversy
to the lay and scientific communities. These
data are the first to unequivocally implicate
the antiandrogenic activity of EDCs as
causative factors in the etiology of prostatitis
in the rat, providing novel insight to the ori-
gins of this disease for which > 90% of human
cases are of unknown cause (McNaughton-
Collins et al. 2007).
The longer-term consequences of in utero
vinclozolin exposure include the development
of gross malformations of the male reproduc-
tive tract, such as the epididymis, vas deferens,
SVs, prostate, external genitalia (hypospadias),
cryptorchidism and testicular injury, and per-
manent change in sexually dimorphic struc-
tures (Wolf et al. 2000). A reduction in nuclear
epithelial AR in prostate tissues from animals
exposed in utero to vinclozolin correlates with
previous studies demonstrating rapid AR
degradation after antiandrogen binding (Wong
et al. 1995).
The immediate effects of reduced AR and
mesenchymal Fgf10 expression in tissues
exposed in utero to vinclozolin do not result in
any perturbations in prostate branching. This
implies that other androgen-regulated paracrine
factors produced by the mesenchyme were
sufficient to compensate and induce normal
differentiation and development. Furthermore,
the absence of a branching effect after in utero
treatment during primary gland genesis may
indicate that Fgf10 acts only with concurrent
chemical exposure in the neonate when sec-
ondary branching morphogenesis occurs. These
findings are in contrast with effects reported
after neonatal estrogen exposure, in which
reductions in mesenchymal Fgf10 inhibit
branching morphogenesis (Huang et al. 2005).
Prostatic inﬂammation is a common fea-
ture of endocrine disruption by estrogenic and
antiandrogenic chemicals (Naslund et al. 1988;
Prins 1997; Stoker et al. 1999). Results of the
present study demonstrate the absence of any
morphologic changes before puberty but an
inflammatory response in all young post-
pubertal (PND56) prostates after in utero anti-
androgenic exposure. Activation of the NFκB
inﬂammatory pathway was evident, with a sig-
nificant down-regulation of AR expression.
There is considerable evidence to show
crosstalk between AR and NFκB (De Bosscher
et al. 2006); thus, it is reasonable to postulate
that the persistent repression of AR signaling
induced by vinclozolin results in androgenic
activity that is insufﬁcient to suppress NFκB
signaling pathways, resulting in inappropriate
activation of NFκB and the emergence of pro-
statitis. Although the exact mechanism by
which estradiol exposure promotes an inﬂam-
matory response in the adult prostate has not
yet been determined, antiandrogen-induced
inﬂammation is associated with activation of
the “canonical” proinflammatory NFκB
inflammatory signaling pathway and NFκB-
dependent genes.
There are further important differences
between EDCs that are antiandrogenic or
estrogenic. In contrast with estrogen-induced
inflammation, the long-term effects of tran-
sient in utero exposure to vinclozolin failed to
induce premalignancy. Inﬂammation and focal
atrophy associated with increased proliferation
have been described in human prostate speci-
mens as PIA and may be premalignant. The
pathology arising from in utero vinclozolin
treatment and described herein does show
inﬂammation and focal epithelial attenuation
but in the absence of increased proliferation.
Therefore, we conclude that vinclozolin did
not induce the premalignant lesion PIA.
Conclusions
Overall, the robust incidence of inﬂammation
in 100% of young adult rats more closely mim-
ics human nonbacterial prostatitis that occurs
in young men. Ninety percent of prostatitis
cases are of unknown cause, and these data are
the ﬁrst to implicate antiandrogenic EDCs as a
causative factor in the etiology of this inﬂam-
matory disease of the prostate via activation of
the classical NFκB inflammatory pathway.
Although the level of vinclozolin used in this
study far exceeds that observed in the environ-
ment and projected human exposure, these
Cowin et al.
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Figure 4. Epithelial attenuation in postpubertal animals after in utero corn oil (control) or vinclozolin treatment. (A–D) Photomicrographs of prostates from control
(A,C) and vinclozin-exposed (B,D) rats showing immunolocalization of AR (A,B) and CKHMW (C,D). In tissues from controls (A), AR is localized predominately to
epithelial cells, but a down-regulation in epithelial AR expression is observed in vinclozolin-exposed prostates (B). Immunolocalization for CKHMW indicated a
discontinuous layer of basal cells in control tissues (C) compared with a continuous layer in prostates from vinclozolin-exposed animals (D). (E) Stereologic analy-
sis showing a significant loss of terminally differentiated epithelial cells in vinclozolin-exposed animals compared with controls; data are mean ± SE.
(F,G) Proliferative activity examined by immunolocalization of PCNA. A reduction in immunopositive epithelial cells was observed in attenuated glands of prostate
tissues from vinclozolin-exposed animals (G) compared with controls (F). Bars = 100 µm in A and B; 50 µm in C and D; and 200 µm in F and G.
*p < 0.05.
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results raise further concerns that in utero expo-
sures to EDCs with antiandrogenic activity
have long-range effects that include the devel-
opment of prostatitis in early adult life. Our
results also provide further impetus to test the
efficacy of treatments that block or abrogate
NFκB signaling in the treatment of prostatitis.
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